![Inside the Lab Industry: Q3 Earnings Signal Beginning of the End of ‘COVID-19 Hangover’](https://www.g2intelligence.com/wp-content/uploads/2023/12/Jan24.QuarterlyReport.Q3EarningsReports-iStock-1219172911_1100x800-1080x675.jpg)
Inside the Lab Industry: Q3 Earnings Signal Beginning of the End of ‘COVID-19 Hangover’
What 2023 Q3 earnings from 30 key US lab companies indicate about the current state of the industry and outlook for 2024.
What 2023 Q3 earnings from 30 key US lab companies indicate about the current state of the industry and outlook for 2024.
Recent cases involve Medicare’s 14-Day Rule, improper PHI disclosure to a media outlet, kickbacks, and COVID-19 fraud.
A pandemic-related drop in cancer diagnoses could spell long-term trouble for patients and providers.
A settlement for kickback allegations, prison time for lab owners convicted of COVID-19 fraud, and 10x Genomics gets OK for lawsuit.
Though COVID-19 testing declines continue to negatively affect lab industry profits, the latest figures suggest the worst may be over.